CARDIFF ONCOLOGY, INC. Revenue Not from Contract with Customer
CARDIFF ONCOLOGY, INC. (CRDF) reported Revenue Not from Contract with Customer of $0 for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2020-11-05
- CARDIFF ONCOLOGY, INC. revenue not from contract with customer for the quarter ending 2020-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. revenue not from contract with customer for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. revenue not from contract with customer for the quarter ending 2019-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. revenue not from contract with customer for the quarter ending 2019-06-30 was $1.50K.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-11 | $0.00 10-Q · filed 2020-08-11 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $1.50K derived: sum of 2 quarters · filed 2020-11-05 | $1.50K 10-Q · filed 2020-11-05 |
| 2019-06-30 | $1.50K 10-Q · filed 2020-08-11 | $1.50K 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |